Time to Change Strategy in Non-metastatic Locally Advanced Mismatch Repair-Deficient Colon Cancer

Affiliations

Editorial

Campbell S Roxburgh. Ann Surg Oncol. 2024 Oct.

. 2024 Oct;31(10):6342-6343.

doi: 10.1245/s10434-024-15780-1. Epub 2024 Jul 11.

¹ Colorectal Surgical Oncology, Glasgow Royal Infirmary, School of Cancer Sciences, University of Glasgow, Glasgow, UK. campbell.roxburgh@glasgow.ac.uk.

No abstract available

References

1. Smith HG, Schlesinger NH, Chiranth D, Qvortrup C. The association of mismatch repair status with microscopically positive (R1) margins in Stage III colorectal cancer: a retrospective cohort study. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15595-0 . - DOI - PubMed - PMC
1. Klein MF, Gogenur I, Ingeholm P, Njor SH, Iversen LH, Emmertsen KJ, DCCG Validation Group. Validation of the Danish Colorectal Cancer Group (DCCG.dk) database—on behalf of the Danish Colorectal Cancer Group. Colorectal Dis. 2020;22(12):2057–67.
1. Morton D, Seymour M, Magill L, Handley K, Glasbey J, Glimelius B, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541–52. - DOI - PubMed - PMC
1. Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071. - DOI - PubMed - PMC
1. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–76. - DOI - PubMed - PMC